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• Tissue Macro Array (TMA) and Targeted-Next Generation Sequencing (T-NGS) analyses
IDENTIFICATION OF PUTATIVE DRIVER AND ACTIONABLE CANCER GENES
WES AND CNA ANALYSES OF 12 PDX lines
(naive,TP53 mutated, HGS-EOCs, collected from 
patients treated with cytoreductive surgery and platinum-
based chemotherapy)
SOMATIC SNVs IDENTIFICATION
IDENTIFICATION OF PUTATIVE 
ACTIONABLE DRIVERS
SELECTION OF THE IDENTIFIED SNVs
WITH AF ≥ 0.1 IN CANCER-RELATED 
GENES LISTED IN COSMIC
Olivero M. & Arigoni M.
PYROSEQUENCING OF 
SOURCE TUMOR SAMPLES
PUTATIVE DRIVER AND ACTIONABLE SNVs IN CANCER GENES
PIK3R1
47
5
Modified from: “Shield K. Gynecol Oncol 2009 “
EX VIVO AND IN VIVO ASSAYS OF PI3K INHIBITORS 
ON #475 PDX LINE
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EX-VIVO ASSAYS OF PI3K INHIBITORS ON #475 PDTCs
• Buparlisib and Dactolisib (72h Viability assay and Western Blot analysis)
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EX-VIVO ASSAYS OF PI3K INHIBITORS ON #475 PDTCs
• Alpelisib and GSK2636771  (72h Viability assay and Western Blot analisys)
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CTRL
• Buparlisib 20mg/Kg
IN VIVO ASSAY OF BUPARLISIB ON #475 PDXs
• Western Blot analysis
at the end of in vivo treatment
CONCLUSIONS
• PIK3R1W624R mutation is an actionable mutation in HGS-EOC and it makes the 
tumor susceptible to PI3K inhibitors
• We show the utility of a PDX-based pipeline to study and identify new driver 
and actionable mutations in HGS-EOC
• PDXs and PDTCs models of ovarian cancer are invaluable tools to assay 
actionability when sequence- and structure-based* prediction are inadequate
* data not shown
THANK YOU!
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Ovarian Cancer (OC): Fifth most lethal gynecological cancer 
among woman in the world derived from:
• Epithelial cells (EOC): more than 90% mostly malignant 
• Stromal cells: 5-6%
• Germ cells: 2-3%
INTRODUCTION
Adapted from: Brett M. Reid et al. Cancer Biol Med 2017
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Mutated gene
• Long Tail Distribution of mutated cancer genes in ovarian cancer
1078 mutated genes in 315 High Grade Serous Ovarian Cancer reported in TCGA analyses with WES
INTRODUCTION
Adapted from: TCGA data (https://cancergenome.nih.gov)
ASSAYED PI3K INHIBITORS
Buparlisib (BKM120)
Pan-class I PI3K inhibitor
Dactolisib (BEZ235)
Dual mTOR/PI3K inhibitor
Alpelisib (BYL719)
P110α selective inhibitor
GSK2636771
P110β selective inhibitor
Adapted from: http://www.selleckchem.com/products.html
IDENTIFICATION OF ACTIONABLE CANCER GENE MUTATIONS 
IN PATIENT DERIVED XENOGRAFTS (PDXs) DERIVED FROM HIGH GRADE 
SEROUS EPITHELIAL OVARIAN CANCER (HGS-EOC)
1. Characterization of PDX lines
2. WES and CNA analyses of selected PDX lines
3. Identification of SNVs in cancer genes
4. Evaluating the functional impact using SIFT, PROVEAN and FATHHMN algorythms
5. Ex vivo assays of targeted drugs on PDX-Derived Tumor cells (PDTCs) 
6. In vivo assays of targeted drugs on PDXs
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